Video Upload Options

References

1. Bergemann AD, Cole F, Hirschhorn K. The etiology of Wolf-Hirschhorn syndrome. Trends Genet. 2005 Mar;21(3):188-95. Review.
2. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ. Molecular mechanisms underlyingFIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res. 2007 Apr 15;67(8):3759-66.
3. Chen CP, Chern SR, Lee CC, Chang TY, Wang W, Tzen CY. Clinical, cytogenetic,and molecular findings of prenatally diagnosed mosaic trisomy 4. Prenat Diagn.2004 Jan;24(1):38-44. Review.
4. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, ClarkJ, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL,Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, KantarjianH, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created byfusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib inidiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14.
5. Goldfrank D, Schoenberger E, Gilbert F. Disease genes and chromosomes: diseasemaps of the human genome. Chromosome 4. Genet Test. 2003 Winter;7(4):351-72.
6. Hayne CC, Winer E, Williams T, Chaves F, Khorsand J, Mark HF. Acutelymphoblastic leukemia with 4;11 translocation analyzed by a multi-modal strategyof conventional cytogenetics, FISH, morphology, flow cytometry and moleculargenetics, and review of the literature. Exp Mol Pathol. 2006 Aug;81(1):62-71.
7. Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P,Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, DelehauntyKD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, AliJ, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L,Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M,Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W,Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J,Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S,Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L,Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, CookLL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD,Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD,Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH,Wilson RK. Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31.
8. Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, LarrattLM, Mant MJ, Reiman T, Belch AR, Pilarski LM. Overexpression of transcriptsoriginating from the MMSET locus characterizes all t(4;14)(p16;q32)-positivemultiple myeloma patients. Blood. 2005 May 15;105(10):4060-9.
9. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma. 2006Nov;47(11):2289-300. Review.
10. Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camaño P, Dauwerse JG,Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, TawilR, Frants RR, van der Maarel SM. A unifying genetic model for facioscapulohumeralmuscular dystrophy. Science. 2010 Sep 24;329(5999):1650-3. doi:10.1126/science.1189044.
11. Lundin C, Zech L, Sjörs K, Wadelius C, Annerén G. Trisomy 4q syndrome:presentation of a new case and review of the literature. Ann Genet. 2002Apr-Jun;45(2):53-7. Review.
12. South ST, Hannes F, Fisch GS, Vermeesch JR, Zollino M. Pathogenic significanceof deletions distal to the currently described Wolf-Hirschhorn syndrome critical regions on 4p16.3. Am J Med Genet C Semin Med Genet. 2008 Nov 15;148C(4):270-4.doi: 10.1002/ajmg.c.30188.
13. Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: thepath to consensus on pathophysiology. Skelet Muscle. 2014 Jun 10;4:12. doi:10.1186/2044-5040-4-12.
14. Zollino M, Lecce R, Fischetto R, Murdolo M, Faravelli F, Selicorni A, Buttè C,Memo L, Capovilla G, Neri G. Mapping the Wolf-Hirschhorn syndrome phenotypeoutside the currently accepted WHS critical region and defining a new criticalregion, WHSCR-2. Am J Hum Genet. 2003 Mar;72(3):590-7.
15. Zollino M, Murdolo M, Marangi G, Pecile V, Galasso C, Mazzanti L, Neri G. Onthe nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotypecorrelation analysis of 80 patients and literature review. Am J Med Genet C SeminMed Genet. 2008 Nov 15;148C(4):257-69. doi: 10.1002/ajmg.c.30190. Review.